Sigilon Therapeutics Inc expected to post a loss of 34  cents a share - Earnings Preview

Sigilon Therapeutics

14/03/2022 23:31

* Sigilon Therapeutics Inc  SGTX.OQ   SGTX.O  is expected
to show
a rise in quarterly revenue when it reports  results on March 16
(estimated). 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 8.2% increase in revenue to $3.2 million from $2.96 million a
year ago, according to the estimate from one analyst, based on
Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Sigilon
Therapeutics Inc
is for a loss of 34 cents per share. For the same quarter last
year, the company reported a loss of 60 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.7%
in the last three months. ​
    * Wall Street's median 12-month price target for Sigilon
Therapeutics Inc is $7​, above​ its last closing price of $1.29.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.56       -0.56      -0.55     Beat    2.1
 Sep. 30 2021  -0.70       -0.66      -0.63     Beat    4.3
 Jun. 30 2021  -0.57       -0.63      -0.65     Missed  -3.6​
 Mar. 31 2021  -0.61       -0.59      -0.60     Missed  -1.1
 ​​Dec.        -1.37       -1.37      -1.15     Beat    16.1
 31 2020                                                
                                                        ​
 This summary was machine generated March 14 at 23:30 GMT.  All
figures in US dollars  unless otherwise stated